Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma.

chemoresistance glioblastoma lncRNA regulatory circuit temozolomide transcriptome

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
10 Sep 2020
Historique:
received: 17 07 2020
revised: 04 09 2020
accepted: 08 09 2020
entrez: 15 9 2020
pubmed: 16 9 2020
medline: 16 9 2020
Statut: epublish

Résumé

Resistance to chemotherapy by temozolomide (TMZ) is a major cause of glioblastoma (GBM) recurrence. So far, attempts to characterize factors that contribute to TMZ sensitivity have largely focused on protein-coding genes, and failed to provide effective therapeutic targets. Long noncoding RNAs (lncRNAs) are essential regulators of epigenetic-driven cell diversification, yet, their contribution to the transcriptional response to drugs is less understood. Here, we performed RNA-seq and small RNA-seq to provide a comprehensive map of transcriptome regulation upon TMZ in patient-derived GBM stem-like cells displaying different drug sensitivity. In a search for regulatory mechanisms, we integrated thousands of molecular associations stored in public databases to generate a background "RNA interactome". Our systems-level analysis uncovered a coordinated program of TMZ response reflected by regulatory circuits that involve transcription factors, mRNAs, miRNAs, and lncRNAs. We discovered 22 lncRNAs involved in regulatory loops and/or with functional relevance in drug response and prognostic value in gliomas. Thus, the investigation of TMZ-induced gene networks highlights novel RNA-based predictors of chemosensitivity in GBM. The computational modeling used to identify regulatory circuits underlying drug response and prioritizing gene candidates for functional validation is applicable to other datasets.

Identifiants

pubmed: 32927769
pii: cancers12092583
doi: 10.3390/cancers12092583
pmc: PMC7563839
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Fondation Cancer Luxembourg
ID : INCOMING

Références

BMC Med Genomics. 2018 Dec 31;11(Suppl 6):120
pubmed: 30598114
Gene. 2019 May 15;696:1-9
pubmed: 30735718
Neurology. 2011 Mar 29;76(13):1126-34
pubmed: 21346220
Neurosci Lett. 2016 Aug 15;628:161-6
pubmed: 27329239
J Cell Mol Med. 2018 Oct;22(10):4611-4616
pubmed: 30073755
Cancer Chemother Pharmacol. 2009 Oct;64(5):1053-8
pubmed: 19597728
Clin Chim Acta. 2015 Apr 15;444:280-8
pubmed: 25748036
Nucleic Acids Res. 2014 Jan;42(Database issue):D92-7
pubmed: 24297251
Cell Death Dis. 2018 Aug 6;9(8):841
pubmed: 30082680
Cancer Lett. 2015 Apr 1;359(1):75-86
pubmed: 25578780
Anticancer Agents Med Chem. 2014 Jan;14(1):9-17
pubmed: 23387973
Cell Death Dis. 2019 Mar 13;10(3):246
pubmed: 30867410
J Transl Med. 2015 Feb 26;13:74
pubmed: 25886061
Genes Dev. 2011 Sep 15;25(18):1915-27
pubmed: 21890647
Nat Commun. 2019 Apr 16;10(1):1787
pubmed: 30992437
Curr Mol Pharmacol. 2012 Jan;5(1):102-14
pubmed: 22122467
Trends Biochem Sci. 2014 Apr;39(4):170-82
pubmed: 24674738
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Acta Neuropathol. 2012 Oct;124(4):547-60
pubmed: 22810491
Cancers (Basel). 2019 Jun 30;11(7):
pubmed: 31262047
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W77-83
pubmed: 23703215
RNA. 2014 Nov;20(11):1655-65
pubmed: 25323317
Oncogene. 2007 Jan 11;26(2):186-97
pubmed: 16819506
Cell. 2016 Jan 14;164(1-2):69-80
pubmed: 26724866
Cancer Res. 2008 Jul 15;68(14):5706-15
pubmed: 18632623
Mutat Res Rev Mutat Res. 2016 Jul-Sep;769:19-35
pubmed: 27543314
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Nature. 2012 Sep 6;489(7414):101-8
pubmed: 22955620
J Biomol Screen. 2004 Jun;9(4):273-85
pubmed: 15191644
Glia. 2011 Dec;59(12):1974-86
pubmed: 21901757
Bioinformatics. 2012 Aug 1;28(15):2062-3
pubmed: 22718787
Int J Clin Exp Med. 2015 Oct 15;8(10):17110-6
pubmed: 26770304
Pharmacol Ther. 2018 Apr;184:13-41
pubmed: 29080702
Oncotarget. 2016 May 31;7(22):31955-71
pubmed: 27049916
Genome Res. 2014 May;24(5):869-84
pubmed: 24515121
Annu Rev Genet. 2015;49:673-95
pubmed: 26631517
Drug Discov Today. 2015 Jul;20(7):899-905
pubmed: 25744176
Mol Med. 2011 Jan-Feb;17(1-2):103-12
pubmed: 20957337
Mol Cancer Ther. 2013 Nov;12(11):2529-40
pubmed: 23960094
Exp Neurol. 2000 Jan;161(1):67-84
pubmed: 10683274
Nat Struct Mol Biol. 2013 Jul;20(7):908-13
pubmed: 23728290
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Int J Mol Sci. 2020 Mar 05;21(5):
pubmed: 32150871
Cell. 2011 Aug 5;146(3):353-8
pubmed: 21802130
DNA Repair (Amst). 2007 Aug 1;6(8):1079-99
pubmed: 17485253
Cancer Res. 2001 Mar 1;61(5):1957-63
pubmed: 11280752
Genes Dev. 2009 Dec 15;23(24):2839-49
pubmed: 20008935
Nucleic Acids Res. 2013 Jan;41(Database issue):D246-51
pubmed: 23042674
Cell Rep. 2016 Jun 14;15(11):2500-9
pubmed: 27264189
Nucleic Acids Res. 2013 Jan;41(Database issue):D177-87
pubmed: 23161675
J Cell Biochem. 2017 Dec;118(12):4897-4904
pubmed: 28569381
Clin Cancer Res. 2010 May 15;16(10):2715-28
pubmed: 20442299
Science. 2010 Aug 6;329(5992):689-93
pubmed: 20616235
Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8326-31
pubmed: 26111795
Oncotarget. 2017 Nov 28;8(67):110785-110796
pubmed: 29340016
Mol Cancer. 2013 Oct 29;12(1):131
pubmed: 24168400
Cancer Res. 2014 Mar 15;74(6):1651-60
pubmed: 24473064
Nucleic Acids Res. 2013 Apr 1;41(6):e74
pubmed: 23335781
Cell Biosci. 2018 Mar 22;8:23
pubmed: 29588850
Oncotarget. 2016 Jul 5;7(27):41737-41747
pubmed: 27229531
J Biotechnol. 2010 Jul 1;148(1):3-15
pubmed: 20097238
Oncotarget. 2014 Nov 30;5(22):10976-96
pubmed: 25428918
Nat Rev Neurol. 2010 Jan;6(1):39-51
pubmed: 19997073
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
PLoS Comput Biol. 2012;8(7):e1002488
pubmed: 22829753

Auteurs

Sabrina Fritah (S)

NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.

Arnaud Muller (A)

Quantitative Biology Unit, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.

Wei Jiang (W)

Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37203, USA.

Ramkrishna Mitra (R)

Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37203, USA.

Mohamad Sarmini (M)

NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.
Faculty of Science, Technology and Medicine, University of Luxembourg, L-4365 Esch-sur-Alzette, Luxembourg.

Monika Dieterle (M)

NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.

Anna Golebiewska (A)

NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.

Tao Ye (T)

Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique, UMR7104, Institut National de la Santé et de la Recherche Médicale, U964, Université de Strasbourg, 67404 Illkirch, France.

Eric Van Dyck (E)

DNA Repair and Chemoresistance, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.

Christel Herold-Mende (C)

Experimental Neurosurgery, Department of Neurosurgery, University of Heidelberg, 69120 Heidelberg, Germany.

Zhongming Zhao (Z)

Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37203, USA.
School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.

Francisco Azuaje (F)

NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.
Quantitative Biology Unit, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.

Simone P Niclou (SP)

NORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.
Department of Biomedicine, University of Bergen, N-5009 Bergen, Norway.

Classifications MeSH